A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants

Any fever (\>=100.4 degrees Fahrenheit \[\>=38.0 degrees Celsius\], regardless of route) or lower respiratory illness within 7 days prior to randomization

Moderate or severe nasal congestion that in the investigator's opinion could interfere with intranasal delivery of study vaccine

Acute illness (defined as the presence of moderate or severe signs and symptoms) at the time of randomization

Any drug therapy (chronic or other) within 7 days prior to randomization or expected receipt through the protocol-specified blood collection 28 days after each study vaccine dosing, except that infrequent use of over-the-counter medications for the systemic treatment of common childhood symptoms (that is, pain relievers, decongestants or cough suppressants) are permitted according to the judgment of the investigator

Any current or expected receipt of immunosuppressive agents including steroids (\>=2 milligram per kilogram \[mg/kg\] per day of prednisone or its equivalent, or \>=20 milligram per day \[mg/day\] if the subject weighs \>10 kilogram \[kg\], given daily or on alternate days for \>=14 days); children in this category should not receive study vaccine until immunosuppressive agents including corticosteroid therapy have been discontinued for \>=30 days; the use of topical steroids is permitted according to the judgment of the investigator

History of receipt of blood transfusion or expected receipt through the protocol-specified blood collection at 28 days after final study dosing

History of receipt of immunoglobulin products or expected receipt through the protocol-specified blood collection at 28 days after final study dosing

Receipt of any investigational drug within 60 days prior to randomization or expected receipt through 180 days after final study dosing

Receipt of any live virus vaccine (excluding oral polio vaccine and rotavirus vaccine) within 28 days prior to randomization or expected receipt within a 28-day window around any study vaccine dose

Receipt of any inactivated (that is, non-live) vaccine or oral polio vaccine or rotavirus vaccine within 14 days prior to randomization or expected receipt within a 14-day window around any study vaccine dose

Known or suspected immunodeficiency, including human immunodeficiency virus (HIV) infection

Expected to be living in the same home or enrolled in the same classroom at day care with infants \<6 months within 28 days after each dose

Living in a household with another child who is concurrently enrolled in a study of a live viral vaccine (including this study)

Expected contact with a pregnant caregiver within 28 days after each dose

A household contact who is immunocompromised; the subject should also avoid close contact with immunocompromised individuals for at least 28 days after any study vaccine dose

Expected household contact within 28 days after each dose with a health care provider for immunocompromised subjects or who is a day care provider for infants under the age of 6 months

History of allergic reaction to any component of the study vaccine

Previous medical history, or evidence, of an intercurrent or chronic illness that, in the opinion of the investigator, may compromise the safety of the subject

Known or suspected active or chronic hepatitis infection

History of medical diagnosis of asthma, reactive airway disease, wheezing requiring medication, cystic fibrosis, bronchopulmonary dysplasia, chronic pulmonary disease, medically confirmed apnea, hospitalization for respiratory illness or mechanical ventilation for respiratory illness (excludes elective mechanical ventilation during surgery for subjects in Cohorts 1 and 2)

Family member or household contact who is an employee of the research center or otherwise involved with the conduct of the study

Any condition that, in the opinion of the investigator, might interfere with study vaccine evaluation.

What this study is about